Analysts expect Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) to report earnings per share (EPS) of ($0.93) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Madrigal Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.04) and the highest is ($0.84). Madrigal Pharmaceuticals posted earnings of ($0.45) per share in the same quarter last year, which indicates a negative year over year growth rate of 106.7%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, May 14th.

According to Zacks, analysts expect that Madrigal Pharmaceuticals will report full year earnings of ($3.99) per share for the current fiscal year, with EPS estimates ranging from ($4.44) to ($3.60). For the next year, analysts expect that the business will post earnings of ($4.97) per share, with EPS estimates ranging from ($5.40) to ($4.48). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings data on Wednesday, February 27th. The biopharmaceutical company reported ($0.75) EPS for the quarter, meeting analysts’ consensus estimates of ($0.75). During the same quarter last year, the business earned ($0.67) earnings per share.

MDGL has been the topic of a number of recent research reports. ValuEngine lowered shares of Madrigal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 30th. Svb Leerink initiated coverage on shares of Madrigal Pharmaceuticals in a research note on Friday, February 22nd. They issued an “outperform” rating and a $165.00 price objective on the stock. UBS Group initiated coverage on shares of Madrigal Pharmaceuticals in a research note on Wednesday, January 23rd. They issued a “neutral” rating and a $119.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $228.00 target price (down previously from $313.00) on shares of Madrigal Pharmaceuticals in a report on Thursday, February 28th. Finally, Leerink Swann initiated coverage on shares of Madrigal Pharmaceuticals in a report on Friday, February 22nd. They issued an “outperform” rating on the stock. Two analysts have rated the stock with a sell rating, three have given a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $223.36.

NASDAQ MDGL traded down $1.75 during trading on Wednesday, reaching $103.81. The company’s stock had a trading volume of 62,866 shares, compared to its average volume of 240,553. The firm has a market cap of $1.63 billion, a PE ratio of -46.76 and a beta of 1.19. Madrigal Pharmaceuticals has a twelve month low of $91.56 and a twelve month high of $325.98.

Several large investors have recently modified their holdings of the company. Vanguard Group Inc boosted its holdings in Madrigal Pharmaceuticals by 52.7% during the third quarter. Vanguard Group Inc now owns 706,318 shares of the biopharmaceutical company’s stock worth $151,243,000 after buying an additional 243,664 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Madrigal Pharmaceuticals by 52.7% during the third quarter. Vanguard Group Inc. now owns 706,318 shares of the biopharmaceutical company’s stock worth $151,243,000 after buying an additional 243,664 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in Madrigal Pharmaceuticals during the third quarter worth about $20,300,000. BlackRock Inc. boosted its holdings in Madrigal Pharmaceuticals by 17.7% during the third quarter. BlackRock Inc. now owns 575,019 shares of the biopharmaceutical company’s stock worth $123,130,000 after buying an additional 86,520 shares in the last quarter. Finally, Frontier Capital Management Co. LLC purchased a new stake in Madrigal Pharmaceuticals during the fourth quarter worth about $9,454,000. 58.28% of the stock is currently owned by institutional investors and hedge funds.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.

See Also: How are Outstanding Shares Different from Authorized Shares?

Get a free copy of the Zacks research report on Madrigal Pharmaceuticals (MDGL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.